Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Brazil looks to new Pfizer contract to speed up vaccinations

05/03/2021 | 04:42pm EDT

SAO PAULO, May 3 (Reuters) - Brazil is close to signing a second contract with Pfizer Inc for another 100 million doses of its COVID-19 vaccine, of which 35 million shots are due to be delivered in October, Brazil's Health Minister Marcelo Queiroga said on Monday.

That raises to 200 million doses of the Pfizer shot for Brazil this year, he said, aimed at relieving the shortage of vaccines contributing to the world's second-deadliest outbreak outside the United States.

Rio de Janeiro, Brazil's second-largest city, announced over the weekend that it was delaying second doses of CoronaVac, the vaccine made by China's Sinovac Biotech, because it was running out of shots. The second dose will only be applied every other day until more supplies arrive from the finishing facility at the Butantan biomedical center in Sao Paulo.

Most COVID-19 shots administered so far in Brazil have been CoronaVac, but the Butantan finishing line halted two weeks ago due to delayed shipments of active ingredients from China.

A new load of the ingredient, enough for 5 million doses of CoronaVac, arrived in Brazil on April 19.

So far, Butantan has delivered 42 million doses of CoronaVac to the national immunization program, compared to 26.5 million doses of the AstraZeneca PLC vaccine filled and finished by Fiocruz biomedical center in Rio de Janeiro.

Brazil's Health Ministry received its first 1 million doses of the Pfizer vaccine last week.

Speaking to industry leaders in Sao Paulo, Queiroga said the second contract with Pfizer would double the 100 million doses already signed for the vaccine, which are due for delivery by the end of September.

Queiroga blamed what he saw as failures in intensive care wards for the large toll caused by COVID-19 in Brazil, which has passed 407,000 confirmed deaths.

"We cannot accept that out of every 10 patients who are intubated, eight die. That is why we have so many deaths, because health care does not give the answer we expect from it," said Queiroga, who took office in March as Brazil's fourth health minister tackling its worsening pandemic.

On Monday, a parliamentary inquiry began to hear testimony in a Senate investigation into the handling of the coronavirus crisis by the government of far-right President Jair Bolsonaro, who has repeatedly denied the gravity of the virus, opposed lockdowns and was slow to ensure vaccine supplies last year. (Reporting by Eduardo Simoes Additional reporting by Rodrigo Viga in Rio de Janeiro Writing by Anthony Boadle; Editing by Aurora Ellis)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.72% 7735 Delayed Quote.5.61%
EURO / BRAZILIAN REAL (EUR/BRL) 0.01% 6.3651 Delayed Quote.0.31%
PFIZER, INC. 1.00% 39.58 Delayed Quote.6.47%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.0.00%
All news about SINOVAC BIOTECH LTD.
05/07SINOVAC BIOTECH  : WHO gives emergency approval to first Chinese COVID-19 vaccin..
RE
05/03Brazil looks to new Pfizer contract to speed up vaccinations
RE
04/30SINOVAC BIOTECH  : Brazil pharma flags 'retaliation' risk over bill to drop vacc..
RE
04/27SINOVAC BIOTECH  : Hong Kong to reopen bars, nightclubs from April 29 for vaccin..
RE
04/26WHO expects decision on two Chinese COVID-19 vaccines in next two weeks
RE
04/26Moderna vaccine to be reviewed for WHO emergency listing on April 30 - WHO sp..
RE
04/26SCICLONE PHARMACEUTICALS  : Pharma tests hepatitis drug as COVID-19 vaccine enha..
RE
04/23SINOVAC BIOTECH  : Q4 Adjusted Profit, Sales Rise
MT
04/22SINOVAC : Q4 Earnings Snapshot
AQ
04/22SINOVAC BIOTECH  : Reports Unaudited Fourth Quarter 2020 Financial Results and F..
BU
More news
Financials (USD)
Sales 2020 511 M - -
Net income 2020 110 M - -
Net cash 2020 1 040 M - -
P/E ratio 2020 6,66x
Yield 2020 -
Capitalization 642 M 642 M -
EV / Sales 2019 1,86x
EV / Sales 2020 -0,78x
Nbr of Employees 1 959
Free-Float 63,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang CFO & Vice President-Business Development
Qiang Gao Chief Operating Officer & Vice President
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.0.00%642
CSL LIMITED-3.06%98 042
WUXI BIOLOGICS (CAYMAN) INC.-0.97%55 241
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.35.79%49 953
SAMSUNG BIOLOGICS CO.,LTD.-2.66%47 812
BIOGEN INC.11.92%41 258